Merck and Moderna’s Intismeran Autogene Plus Keytruda Meets Phase 3 RFS and DMFS Endpoints in Resected Melanoma
FDA Grants HDE Approval to OncoSil for Distal Cholangiocarcinoma
FDA Lists More Than 1,500 AI-Enabled Medical Devices as Oncology Applications Expand
Bridging the Care Gap: Expanding Humanitarian Access to CLL Treatment Across LMICs
Simplify Your ESO College Enrolment With Our New 3-Year Plan - ESO
ENZAMET: Enzalutamide Maintains Long-Term Survival Benefit in mHSPC
oncoHUB and OncoDaily Announce Strategic Partnership to Strengthen Ukrainian Oncology
Human Connection in Cancer Care with Dr. Aleksandra Filipovic - CancerWorld
The 2026 Accelerating Anticancer Agent Development and Validation (AAADV) Workshop will take place on November 5–6, 2026, at the Bethesda North Marriott Hotel & Conference Center in Maryland, with both in-person and virtual participation. The two-day program will bring together leaders from academia, regulatory agencies, industry, biostatistics, and patient advocacy to discuss major issues in […]
